Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
|
|
Viridian Therapeutics, Inc. (MGEN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP reports a 4.7% stake in Viridian Therapeutics Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 2.7% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| TCG Crossover GP I, LLC reports a 2.4% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.6% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/26/2023 |
SC 13G/A
| MILLENNIUM MANAGEMENT LLC reports a 2% stake in VIRIDIAN THERAPEUTICS, INC. |
| 08/12/2022 |
SC 13G/A
| Frazier Life Sciences Public Fund, L.P. reports a 1.1% stake in Viridian Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Venrock Healthcare Capital Partners III, L.P. reports a 10% stake in Viridian Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in VIRIDIAN THERAPEUTICS, INC. |
| 02/14/2022 |
SC 13G/A
| D. E. SHAW & CO, L.P. reports a 3.5% stake in Viridian Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.3% stake in Viridian Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Logos Global Management LP reports a 0% stake in Viridian Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Viridian Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| CITADEL ADVISORS LLC reports a 4.3% stake in Viridian Therapeutics, Inc. |
| 02/11/2022 |
SC 13G/A
| Ally Bridge MedAlpha Master Fund L.P. reports a 2.8% stake in Viridian Therapeutics, Inc. |
| 02/04/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/28/2022 |
SC 13G/A
| Frazier Life Sciences Public Fund, L.P. reports a 6.9% stake in Viridian Therapeutics, Inc. |
| 10/08/2021 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 0% stake in VIRIDIAN THERAPEUTICS, INC. |
| 09/29/2021 |
SC 13G/A
| Logos Global Management LP reports a 8.8% stake in Viridian Therapeutics, Inc. |
| 09/29/2021 |
SC 13G/A
| TCG Crossover Management, LLC reports a 8.2% stake in Viridian Therapeutics, Inc. |
| 09/24/2021 |
SC 13G/A
| TCG Crossover Management, LLC reports a 13.7% stake in Viridian Therapeutics, Inc. |
| 06/01/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/15/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/16/2020 |
SC 13G/A
| Logos Global Management LP reports a 14.1% stake in Miragen Therapeutics, Inc. |
| 11/10/2020 |
SC 13G/A
| FMR LLC reports a 0% stake in MIRAGEN THERAPEUTICS |
| 02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/13/2018 |
SC 13G/A
| FMR LLC reports a 9.4% stake in MIRAGEN THERAPEUTICS |
| 01/30/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/24/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
|
|